AI assistant
Adaptive Biotechnologies Corp — Director's Dealing 2020
Aug 15, 2020
31660_dirs_2020-08-14_3dda3bea-3f99-4e90-9a89-d9cf2ca838c2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-08-06
Reporting Person: BOBULSKY SUSAN (SVP, Diagnostics, clonoSEQ)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.98 | 2024-10-13 | Common Stock (65000) | Direct | |
| Stock Option (Right to Buy) | $6.27 | 2027-04-25 | Common Stock (20000) | Direct | |
| Stock Option (Right to Buy) | $6.55 | 2028-04-24 | Common Stock (28750) | Direct | |
| Stock Option (Right to Buy) | $28.32 | 2030-02-27 | Common Stock (13474) | Direct |
Footnotes
F1: All options are fully exercisable.
F2: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F3: The options vested with respect to 1/4 of such shares on April 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F4: The options will vest with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.